Earlier in 2024, DLA Piper published its Medical Devices Advertising: CEE Comparison Guide, which reviews advertising regulations for medical devices in Austria, Croatia, the Czech Republic, Hungary, Poland, Romania, Slovakia, and Slovenia. Life sciences team members who worked on the guide spoke with CEE Legal Matters about some of the regulatory differences across CEE and the practical implications for businesses.

Boyanov & Co has advised Bulgarian pharma company Sopharma on its acquisition of a pharmaceutical product portfolio consisting of both CHC and prescription products.

The amendments to the Bulgarian Public Health Act (PHA), introduced on 8 October 2024, are aimed at modernising the healthcare system, enhancing data management and improving patient care. They prioritise the transition to electronic health records (EHR), regulate telemedicine, and introduce a digital scheduling system for medical appointments. This article provides a high-level overview of the amendments.

Aksan has advised Pharmacontract on obtaining clearance from the Turkish Competition Board for the acquisition of unspecified subsidiaries in Italy.

B2RLaw, working with Pillsbury Winthrop Shaw Pittman, has advised Neuca and Humaneva on the sale of a minority stake in Humaneva to Viking Global Investors for USD 50 million. Clifford Chance advised Viking Global Investors.

Gide has advised Amethyst Radiotherapy Group on EUR 360 million refinancing from Ares Management and other financial institutions.